News & Events

Press Releases

April 3rd, 2019

AgomAb Therapeutics Completes €21m Series A Financing

AgomAb Therapeutics N.V., a privately held Belgian biotherapeutics company developing agonistic antibodies for regeneration of damaged tissues, announces today that it has secured €21m in a Series A financing round from a strong international investor syndicate.


End of content

No more pages to load

Looking to connect with us?

BIO Digital
June 10-18, 2021

Kempen Life Sciences Crossover Conference 
June 16, 2021

J.P. Morgan European Healthcare Conference 
June 17, 2021

Belfius Kepler Cheuvreux Belgian Life Science Day
June 22, 2021

Solebury Trout & Venrock’s 5th Annual EU Investor Tour 
July 13, 2021

LifeSci Advisors – Annual Private Summer Symposium 
July 21-23, 2021

Knowledge for Growth
September 27-29, 2021
Ghent, Belgium


By continuing to use the site, you agree to the use of cookies. Privacy Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.